Department of Respiratory Medicine, The Fourth People's Hospital of Guiyang, Guiyang, Guizhou 550002, P.R. China.
Department of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong 510120, P.R. China.
Mol Med Rep. 2018 Jun;17(6):7683-7691. doi: 10.3892/mmr.2018.8853. Epub 2018 Apr 5.
Non‑small‑cell lung cancer (NSCLC) is one of the most common malignancies that is responsible for a high level of cancer‑associated mortalities worldwide. Previous evidence has shown that Calotropin is an upstream activator of protein kinase B, which can further inhibit the growth and promote the apoptosis of NSCLC cells. In the present study, the efficacy of Calotropin on growth, aggressiveness and apoptosis of NSCLC cells was investigated, as well as the potential underlying mechanism. The results demonstrated that Calotropin inhibited H358 cell growth, migration and invasion. Flow cytometry assay showed that Calotropin promoted the apoptosis of H358 cells in vitro. Western blot analysis demonstrated that Calotropin inhibited fibronectin (FN), Vimentin (VIM) and E‑cadherin (Eca) protein expression levels in H358 cells in vitro. In addition, Calotropin treatment upregulated pro‑apoptosis gene expression, including caspase‑3, caspase‑8 and apoptotic protease activating factor‑1, and downregulated anti‑apoptosis gene expression, including P53, B‑cell lymphoma (Bcl) 2 and Bcl‑2‑like protein 2 in H358 cells. The results also revealed that the expression levels of cytotoxic T‑lymphocyte associated antigen 4 (CTLA‑4) were decreased by Calotropin treatment in H358 cells. Analyses of the underlying mechanism indicated that Calotropin inhibited transforming growth factor‑β (TGF‑β) and extracellular signal‑regulated kinase (ERK) expression. Overexpression of CTLA‑4 inhibited Calotropin‑mediated downregulation of TGF‑β and ERK expression in H358 cells. In vivo assay revealed that Calotropin administration significantly inhibited tumor growth and prolonged animal survival over the 120‑day observation period. Immunohistochemistry demonstrated that the number of apoptotic cells increased and the expression levels of CTLA‑4 were decreased in the Calotropin‑treated tumor group when compared with control. In addition, the expression levels of TGF‑β and ERK were downregulated in the Calotropin‑treated tumor group compared with control. In conclusion, the results of the present study indicated that Calotropin administration regulated NSCLC apoptosis by downregulating the CTLA‑4‑mediated TGF‑β/ERK signaling pathway, suggesting that Calotropin may be a potential anti‑cancer agent for the treatment of NSCLC.
非小细胞肺癌(NSCLC)是最常见的恶性肿瘤之一,在全球范围内导致了很高的癌症相关死亡率。先前的证据表明,萝芙木碱是蛋白激酶 B 的上游激活剂,可进一步抑制 NSCLC 细胞的生长并促进其凋亡。本研究旨在探讨萝芙木碱对 NSCLC 细胞生长、侵袭和凋亡的影响及其潜在的作用机制。结果表明,萝芙木碱可抑制 H358 细胞的生长、迁移和侵袭。流式细胞术检测结果显示,萝芙木碱可促进 H358 细胞的体外凋亡。Western blot 分析结果表明,萝芙木碱可抑制 H358 细胞中纤连蛋白(FN)、波形蛋白(VIM)和 E-钙黏蛋白(Eca)的蛋白表达水平。此外,萝芙木碱处理可上调促凋亡基因的表达,包括半胱氨酸天冬氨酸蛋白酶(caspase)-3、caspase-8 和凋亡蛋白酶激活因子-1,下调抗凋亡基因的表达,包括 P53、B 细胞淋巴瘤(Bcl)2 和 Bcl-2 样蛋白 2。结果还表明,萝芙木碱处理可降低 H358 细胞中细胞毒性 T 淋巴细胞相关抗原 4(CTLA-4)的表达水平。机制分析表明,萝芙木碱可抑制转化生长因子-β(TGF-β)和细胞外信号调节激酶(ERK)的表达。CTLA-4 的过表达可抑制萝芙木碱介导的 H358 细胞中 TGF-β和 ERK 表达的下调。体内实验结果显示,萝芙木碱给药可显著抑制肿瘤生长,并在 120 天的观察期内延长动物的生存时间。免疫组织化学结果表明,与对照组相比,萝芙木碱治疗组肿瘤组织中凋亡细胞数量增加,CTLA-4 表达水平降低。此外,与对照组相比,萝芙木碱治疗组肿瘤组织中 TGF-β和 ERK 的表达水平下调。综上所述,本研究结果表明,萝芙木碱通过下调 CTLA-4 介导的 TGF-β/ERK 信号通路调节 NSCLC 细胞的凋亡,提示萝芙木碱可能是治疗 NSCLC 的一种潜在抗癌药物。